Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

2-Aminoacetophenone

From Wikipedia, the free encyclopedia
(Redirected fromPhenacylamine)
Phenethylamine derivative

Pharmaceutical compound
2-Aminoacetophenone
Clinical data
Other namesPhenylacylamine; β-Ketophenethylamine; β-Ketophenylethylamine; β-Oxophenethylamine; β-Oxophenylethylamine; β-Keto-PEA; β-Oxo-PEA; βk-PEA; bk-PEA; 2-Aminoacetophenone;ortho-Aminoacetophenone;o-Aminoacetophenone; α-Desmethylcathinone; α-Demethylcathinone; PAL-27; PAL27
Drug classNorepinephrine–dopamine releasing agent;Stimulant
Identifiers
  • 2-amino-1-phenylethanone
CAS Number
PubChemCID
ChemSpider
UNII
ChEBI
ChEMBL
CompTox Dashboard(EPA)
ECHA InfoCard100.009.418Edit this at Wikidata
Chemical and physical data
FormulaC8H9NO
Molar mass135.166 g·mol−1
3D model (JSmol)
  • C1=CC=C(C=C1)C(=O)CN
  • InChI=1S/C8H9NO/c9-6-8(10)7-4-2-1-3-5-7/h1-5H,6,9H2
  • Key:HEQOJEGTZCTHCF-UHFFFAOYSA-N

2-Aminoacetophenone, also known asβ-ketophenethylamine,α-desmethylcathinone, orphenacylamine, is asubstituted phenethylaminederivative.[1][2] It is the phenethylamine homologue ofcathinone (β-ketoamphetamine) and hence is a parent compound of a large number ofstimulant andentactogendrugs.[1][3][4]

Phenacylamine is alsoactive itself; it is apotentmonoamine releasing agent ofdopamine (EC50Tooltip half-maximal effective concentration = 208 nM)in vitro, whereas it was inactive forserotonin (EC50 > 10,000 nM) and theEC50 fornorepinephrine was not assessed but the drug induced 96% release of norepinephrine at a concentration of 10,000 nM.[2][5] Hence, phenacylamine acts as anorepinephrine–dopamine releasing agent (NDRA).[2][5]

Despite its activityin vitro however, phenacylamine failed to substitute fordextroamphetamine in animaldrug discrimination tests at doses several-fold higher than effective doses of cathinone.[6] It was concluded that, similarly tophenethylamine but in contrast toamphetamine and cathinone, phenylacylamine is likely to be rapidly inactivated viamonoamine oxidase (MAO)-mediatedmetabolismin vivo and will be inactive without concomitant use of amonoamine oxidase inhibitor (MAOI).[6] It has also been suggested that phenacylamine may have diminishedblood–brain barrierpermeability and limitedcentral activity due to its decreasedlipophilicity relative to cathinone.[7]

See also

[edit]

References

[edit]
  1. ^abKatz DP, Bhattacharya D, Bhattacharya S, Deruiter J, Clark CR, Suppiramaniam V, et al. (September 2014). "Synthetic cathinones: "a khat and mouse game"".Toxicology Letters.229 (2):349–356.doi:10.1016/j.toxlet.2014.06.020.PMID 24973490.
  2. ^abcReith ME, Blough BE, Hong WC, Jones KT, Schmitt KC, Baumann MH, et al. (February 2015)."Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter".Drug and Alcohol Dependence.147:1–19.doi:10.1016/j.drugalcdep.2014.12.005.PMC 4297708.PMID 25548026.
  3. ^Kolesnikova TO, Khatsko SL, Demin KA, Shevyrin VA, Kalueff AV (January 2019). "DARK Classics in Chemical Neuroscience: α-Pyrrolidinovalerophenone ("Flakka")".ACS Chemical Neuroscience.10 (1):168–174.doi:10.1021/acschemneuro.8b00525.PMID 30384587.
  4. ^German CL, Fleckenstein AE, Hanson GR (February 2014)."Bath salts and synthetic cathinones: an emerging designer drug phenomenon".Life Sciences.97 (1):2–8.doi:10.1016/j.lfs.2013.07.023.PMC 3909723.PMID 23911668.
  5. ^abBlough BE, Decker AM, Landavazo A, Namjoshi OA, Partilla JS, Baumann MH, et al. (March 2019)."The dopamine, serotonin and norepinephrine releasing activities of a series of methcathinone analogs in male rat brain synaptosomes".Psychopharmacology.236 (3):915–924.doi:10.1007/s00213-018-5063-9.PMC 6475490.PMID 30341459.
  6. ^abGlennon RA, Young R, Hauck AE, McKenney JD (December 1984). "Structure-activity studies on amphetamine analogs using drug discrimination methodology".Pharmacol Biochem Behav.21 (6):895–901.doi:10.1016/s0091-3057(84)80071-4.PMID 6522418.
  7. ^Glennon RA (2014)."Bath salts, mephedrone, and methylenedioxypyrovalerone as emerging illicit drugs that will need targeted therapeutic intervention".Adv Pharmacol.69:581–620.doi:10.1016/B978-0-12-420118-7.00015-9.PMC 4471862.PMID 24484988.
Adamantanes
Adenosine antagonists
Alkylamines
Ampakines
Arylcyclohexylamines
Benzazepines
Cathinones
Cholinergics
Convulsants
Eugeroics
Oxazolines
Phenethylamines
Phenylmorpholines
Piperazines
Piperidines
Phenethylpyrrolidines
Racetams
Psychedelics
Tropanes
Tryptamines
Others
DRAsTooltip Dopamine releasing agents
NRAsTooltip Norepinephrine releasing agents
SRAsTooltip Serotonin releasing agents
Others
Phenethylamines
Amphetamines
Phentermines
Cathinones
Phenylisobutylamines
(and further-extended)
Catecholamines
(and close relatives)
Cyclized
phenethylamines
Phenylalkylpyrrolidines
2-Benzylpiperidines
(phenidates)
Phenylmorpholines
(phenmetrazines)
Phenyloxazolamines
(aminorexes)
Isoquinolines and
tetrahydroisoquinolines
2-Aminoindanes
2-Aminotetralins
Others / unsorted
Related compounds
Retrieved from "https://en.wikipedia.org/w/index.php?title=2-Aminoacetophenone&oldid=1309405819"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp